--- title: "MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22" url: "https://aibio.space/news/metavia-shareholders-approve-reverse-split-range-1-5-1-22/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-08" section: "Listings" tickers: "NASDAQ:MTVA" source: "https://www.sec.gov/Archives/edgar/data/1638287/000110465926071358/tm2615356d2_8k.htm" summary: "At its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000" --- By the aibio.space news desk. Sources - [MetaVia Inc. 8-K (2026-06-08)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926071358/tm2615356d2_8k.htm) - [MetaVia Inc. 10-K (2026-03-26): business](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm) - [MetaVia Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/) [MTVA](https://aibio.space/companies/metavia/) 2026-06-08 # MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22 Tickers [MTVA](https://aibio.space/companies/metavia/) At its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan. ## Key facts - **Company**: MetaVia Inc. (NASDAQ: MTVA) - **News type**: Listings - **Primary source**: [MetaVia Inc. 8-K (2026-06-08)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926071358/tm2615356d2_8k.htm) *The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.* MetaVia Inc. (Nasdaq: [MTVA](https://aibio.space/companies/metavia/)) said its stockholders approved a reverse stock split at a virtual annual meeting on June 8, 2026. The approved amendment to the company's Third Amended and Restated Certificate of Incorporation would combine every 5 to 22 outstanding shares of common stock into one share. The board will choose the exact ratio within that range. The company reported the votes in a Form 8-K filed the same day. The filing does not say when the board plans to set the ratio. ## The votes A total of 2,866,545 shares of common stock were present or represented online or by proxy, which made up a quorum. On the reverse split proposal, 2,472,949 shares voted for, 373,239 voted against and 20,357 abstained. The filing reports no broker non-votes on that item. Stockholders also approved an amendment to the MetaVia Inc. 2022 Amended and Restated Equity Incentive Plan, as amended on November 29, 2024. The amendment increases the number of shares that may be issued under the plan by 200,000. That proposal drew 1,893,233 votes for, 35,799 against and 5,708 abstentions, with 931,805 broker non-votes. The company's proxy statement, filed with the SEC on April 27, 2026, describes the plan and each proposal in more detail. Two Class I directors were elected to serve until the 2029 annual meeting. D. Gordon Strickland received 1,927,368 votes for and 7,372 withheld. James P. Tursi, M.D. received 1,926,735 votes for and 8,005 withheld. Stockholders also ratified BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 2,772,109 votes for, 89,718 against and 4,718 abstentions. ## The company and its programs MetaVia is a clinical-stage biotechnology company focused on cardiometabolic diseases. Its annual report describes two lead programs. Vanoglipel (DA-1241) is a GPR119 agonist in development for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company started a Phase 2a trial of vanoglipel in 2023, the first-in-human MASH trial for the compound, and said it expected to finalize the Clinical Study Report in the first half of 2026. DA-1726 is an oxyntomodulin analog that acts as a GLP-1 receptor and glucagon receptor dual agonist for obesity. It is designed for once-weekly subcutaneous dosing. The company began a Phase 1 trial in 2024. It announced positive topline data from the up to 32 mg multiple ascending dose cohort in April 2025, began enrolling a higher-dose cohort in June 2025 and dosed the first patient in the non-titrated 48 mg cohort in July 2025. The annual report said the company planned to start Part 3a and Part 3b titration studies in April 2026, with data from both expected in the fourth quarter of 2026. The company also has four legacy programs that it is not planning to advance. It has considered or continues to consider out-licensing or divesting them. ANA001 is an oral niclosamide formulation for moderate COVID-19. NB-01, for painful diabetic neuropathy, was exclusively out-licensed to MThera Pharma Co., LTD. in July 2024. ## Financial position The annual report, filed March 26, 2026, shows research and development expense of $6.8 million for 2025, compared with $21.6 million for 2024. Net loss was $13.0 million for 2025 and $27.6 million for 2024. Cash from operations was negative $15.7 million for 2025 and negative $24.7 million for 2024. Cash and cash equivalents at the end of 2024 were $16.0 million. ## What the vote leaves open The filing gives no reason for the reverse split and no date for it, and a reverse split changes the share count, not the value of the company. The 373,239 votes against on that item were a minority of those cast. The plan amendment adds 200,000 shares to the equity plan, which can dilute holders further. Cash from operations was negative $15.7 million for 2025 against year-end 2024 cash of $16.0 million, and the filing says nothing about current cash. For the two DA-1726 titration studies and the vanoglipel clinical study report, the only timetables are those in the annual report. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story MTVA MetaVia Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/metavia-shareholders-approve-reverse-split-range-1-5-1-22/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22", 2026-06-08, https://aibio.space/news/metavia-shareholders-approve-reverse-split-range-1-5-1-22/